KLHL4 activators constitute a class of compounds that interact with and modulate the activity of Kelch-like protein 4 (KLHL4). KLHL4 is part of the BTB-Kelch superfamily, a group of proteins characterized by a broad-complex, tramtrack, and bric-a-brac (BTB) domain as well as Kelch repeats. These proteins are often implicated in diverse cellular processes, primarily through their role in ubiquitination, a post-translational modification that regulates protein stability and function. KLHL4 activators are designed to enhance the protein's biological activity, which may involve promoting its interaction with Cullin3, a scaffold protein critical in the assembly of Cullin-RING E3 ubiquitin ligases. By doing so, these activators can modulate the ubiquitination of substrates targeted by KLHL4, affecting their degradation or activity. The molecular design of KLHL4 activators often requires an in-depth understanding of the protein's structure to ensure specificity and efficacy in the activation process.
To develop effective KLHL4 activators, researchers employ various techniques such as X-ray crystallography, cryo-electron microscopy, and molecular docking simulations to determine the three-dimensional structure of KLHL4 and identify potential binding sites for small molecules. The compounds are then synthesized and optimized to enhance their interaction with these binding sites, ultimately increasing the functional activity of KLHL4. The chemical properties of these activators are crucial for their function, as they must possess adequate cellular permeability, stability under physiological conditions, and a high degree of selectivity for KLHL4 to avoid off-target effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
A steroidal lactone that has been shown to inhibit the proteasome, which may lead to an increase in KLHL4 activity by reducing its degradation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
An inhibitor of NEDD8-activating enzyme, altering cullin-RING ligase activity, which may impact KLHL4's role in protein ubiquitination. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An irreversible inhibitor of ubiquitin-activating enzyme E1, potentially modulating KLHL4 activity through altering ubiquitin-mediated protein turnover. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
An inhibitor of the deubiquitinase USP14, potentially affecting the degradation rate of proteins and possibly influencing KLHL4 levels. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
A pentacyclic triterpenoid that can disrupt proteasomal activity, possibly leading to increased KLHL4 stability and activity. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
An Hsp90 inhibitor that can lead to the degradation of 'client' proteins; might indirectly affect KLHL4 by modulating protein stability and degradation pathways. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
An inhibitor of the proteasome and other cellular proteases, which could lead to the accumulation of KLHL4, thus increasing its activity in the cell. | ||||||